

# The clinical outcomes of triple antiplatelet therapy versus dual antiplatelet therapy for high-risk patients after coronary stent implantation: a meta-analysis of 11 clinical trials and 9,553 patients

Zhong-Guo Fan<sup>1,\*</sup>  
Guo-Bin Ding<sup>2,\*</sup>  
Xiao-Bo Li<sup>1,3</sup>  
Xiao-Fei Gao<sup>1,3</sup>  
Ya-Li Gao<sup>1</sup>  
Nai-Liang Tian<sup>1,3</sup>

<sup>1</sup>Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, <sup>2</sup>Department of Cardiology, Taixing People's Hospital, Yangzhou University, Taizhou, <sup>3</sup>Department of Cardiology, Nanjing Heart Center, Nanjing, People's Republic of China

\*These authors contributed equally to this work

**Background:** The optimal antiplatelet regimen after in-coronary intervention among patients presenting with complex coronary artery lesions or acute coronary syndrome (ACS) has remained unclear. This study sought to evaluate the clinical outcomes of triple antiplatelet treatment (TAPT) (cilostazol added to aspirin plus clopidogrel) in these patients.

**Methods:** The PubMed, EMBASE, MEDLINE, and other Internet sources were searched for relevant articles. The primary end point was major adverse cardiac events (MACE), including all-cause mortality, myocardial infarction, and target vessel revascularization. The incidence of definite/probable stent thrombosis and bleeding were analyzed as the safety end points.

**Results:** Eleven clinical trials involving 9,553 patients were analyzed. The risk of MACE was significantly decreased following TAPT after stent implantation in the ACS subgroup (odds ratio [OR]: 0.72; 95% confidence interval [CI]: 0.61–0.85;  $P < 0.001$ ), which might mainly result from the lower risk of all-cause mortality in this subset (OR: 0.62; 95% CI: 0.48–0.80;  $P < 0.001$ ). The risk of bleeding was not increased with respect to TAPT.

**Conclusion:** TAPT after stent implantation was associated with feasible benefits on reducing the risk of MACE, especially on reducing the incidence of all-cause mortality among patients suffering from ACS, without higher incidence of bleeding. Larger and more powerful randomized trials are still warranted to prove the superiority of TAPT for such patients.

**Keywords:** triple antiplatelet treatment, dual antiplatelet treatment, stent implantation, complex lesions, acute coronary syndrome

## Introduction

Since the application of the rapidly developed interventional techniques widely in the clinic, improved clinical outcomes have been reported among patients with coronary artery disease (CAD), especially those suffering from acute coronary syndrome (ACS) or presenting with complex coronary artery lesions.<sup>1</sup> Though successful stenting is considered to strengthen these beneficial effects, the risk of stent thrombosis (ST) and restenosis among these patients is still high, which are considered frequent causes of death and recurrent myocardial infarction (MI) derived from the superimposition of a platelet-rich thrombus.<sup>2</sup> As a result, a routine dual antiplatelet treatment (DAPT) consisting of aspirin and a P2Y<sub>12</sub> receptor antagonist has been chosen as an adjuvant therapy after percutaneous coronary intervention (PCI).<sup>3</sup> However, ~10% of patients

Correspondence: Nai-Liang Tian  
Department of Cardiology, Nanjing First Hospital, Nanjing Medical University,  
No 68 Changle Road, Nanjing 210006,  
People's Republic of China  
Tel/fax +86 25 5220 8048  
Email tiannailiang@163.com

undergoing stent implantation receiving DAPT developed thrombotic events leading to high morbidity and mortality,<sup>4,5</sup> which were thought to be driven by high on-treatment platelet reactivity (HTPR).<sup>6</sup> Currently, overcoming HTPR and optimizing the antiplatelet regimen post-PCI for these patients still remain as important problems.

Cilostazol is a selective inhibitor of phosphodiesterase III, which inhibits platelet aggregation in response to ADP, epinephrine, collagen, and arachidonic acid.<sup>7</sup> It can also suppress the production of platelet-derived endothelial cell growth factor, which is considered to drive its extensive application in patients undergoing stent implantation.<sup>7,8</sup>

In recent years, several large observational clinical trials (Obs)<sup>9,10</sup> and meta-analyses<sup>11,12</sup> have demonstrated that adding cilostazol to aspirin plus clopidogrel decreased the risk of major adverse cardiac events (MACE) compared to the conventional dual regimen. A recent meta-analysis published by Bundhun et al,<sup>13</sup> as well as several other randomized trials,<sup>14,15</sup> had stated the superiority of triple antiplatelet therapy (TAPT) for type 2 diabetes mellitus (T2DM) patients after intracoronary stenting procedure. The large randomized controlled trial (RCT) conducted by Lee et al<sup>16</sup> indicated lower risk of late luminal loss, percentage intimal hyperplasia volume, and angiographic restenosis related to the TAPT, resulting in decreased risk of target lesion revascularization (TLR) after 12-month follow-up. However, the COronary Bifurcation Stent (COBIS) II Registry,<sup>17</sup> focused on patients with bifurcation lesions, showed that TAPT post-PCI had no beneficial effects on reducing the risk of long-term clinical outcomes, and another clinical trial<sup>18</sup> showed similar negative results of TAPT among patients suffering from unprotected left main (LM) disease. Of note, patients suffering from ACS or with complex coronary artery lesions are highly likely to develop thrombotic events after stent implantation. These conflicting data have called the optimal antiplatelet regimen into question, and there is no related meta-analysis paying attention to this topic. Therefore, we performed this meta-analysis involving as many related clinical trials as possible to evaluate the efficacy and safety of TAPT compared to DAPT after stent implantation for patients suffering from ACS or with complex coronary artery lesions.

## Methods

### Literature search

The references comparing clinical outcomes of TAPT with DAPT post-PCI among patients presenting with complex coronary artery lesions (defined as long coronary artery lesions, chronic total occlusion lesions, unprotected LM lesions, bifurcation lesions, multivessel artery disease, or

the composite of all these) and/or suffering from ACS were searched in the PubMed, EMBASE, MEDLINE, and the Cochrane Controlled Trials Registry from their dates of inception until June 2016, as well as several other Internet sources. Combinations of several relevant keywords were used to make sure all relevant studies were included, including “triple antiplatelet therapy”, “TAPT”, “dual antiplatelet therapy”, “DAPT”, “acute myocardial infarction or AMI”, “acute coronary syndrome or ACS”, “chronic total occlusion”, “left main”, “bifurcation”, “long lesions”, “stent implantation”, “percutaneous coronary intervention” or “PCI”. All potentially relevant citations and references from published reviews or meta-analyses were subsequently screened for eligibility.

### Inclusion and exclusion criteria

The included studies were required to fulfill the following criteria: 1) adult patients with complex coronary artery lesions and/or suffering from ACS (age range: 18–90 years) undergoing stent implantation; 2) clinical trials comparing the TAPT and the DAPT groups; and 3) reported results of adverse clinical events. The exclusion criteria were as follows: 1) patients with cardiogenic shock; 2) nonhuman or ongoing studies; 3) non-English-language studies; 4) reviews or meta-analyses; and 5) duplicated studies, or different studies using the same sample.

### Data extraction, synthesis, and quality assessment

All relevant articles were reviewed by two independent investigators (FZG and DGB) using standardized data abstraction forms to assess their eligibility. The third investigator (LXB) resolved disagreements. These following data were extracted from each included study: the name or the first author of the trial, publication year, baseline demographics, characteristics of lesions, details of antiplatelet regimens and PCI procedure, as well as clinical outcomes during follow-up. These included trials were divided into two subgroups, described as the “complex lesions” subgroup and the “ACS” subgroup. The quality of all retrieved studies was assessed according to the Newcastle–Ottawa Scale (NOS)<sup>19</sup> and the Jadad score<sup>20</sup> for the cohorts and randomized studies, respectively.

### Study end points

The primary end point of this study was incidence of MACE, including all-cause mortality, MI (including both Q-wave MI and non-Q-wave MI) and target vessel revascularization (TVR) (TLR was used instead in one trial due to the absence of relevant data<sup>10</sup>). The secondary end point was the

risk of stroke. The incidence of definite/probable ST, according to the definition of the Academic Research Consortium,<sup>21</sup> and bleeding, including major and minor bleeding, were chosen to be evaluated as the safety end points. There were slight differences among these included trials in terms of the definitions of clinical end points, and standardized definitions were followed.

## Statistical analysis

This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.<sup>22</sup> STATA 12.0 (StataCorp LP, College Station, TX, USA) was used to perform the statistical analysis. All the end points were applied as dichotomous variables, expressed with odds ratios (ORs) and 95% confidence intervals (CIs). When a *P*-value was less than 0.05, it was considered statistically significant. The Cochran's *Q* test and the *I*<sup>2</sup> statistic were used to measure statistical heterogeneity. Significant heterogeneity was considered and a random-effects model would be selected if the *P*-value of the *Q* test was <0.10 and/or the *I*<sup>2</sup> was ≥50%. In contrast, the fixed-effects model with the Mantel–Haenszel method was used instead. Publication bias was examined via the Egger's test (*P*<0.1 for significant asymmetry).<sup>23</sup> The sensitivity

analyses were also performed by excluding one study at a time to assess the stability of the overall treatment effects. All of the *P*-values were two tailed.


## Results

### Eligible studies and patient characteristics

After screening 996 initial articles through the electronic databases and another 54 articles from several other Internet sources, 11 clinical trials were finally identified, including 7 RCTs<sup>16,24–29</sup> and 4 Obs<sup>9,10,17,18</sup> (Figure 1). Among these included clinical trials, there were 2 trials for long artery lesions,<sup>16,24</sup> 1 for unprotected LM disease,<sup>18</sup> 1 for bifurcation lesion,<sup>17</sup> and 1 for mixed complex lesions.<sup>29</sup> Another 6 clinical trials focused on patients suffering from ACS.<sup>9,10,25–28</sup> Only 1 observational trial<sup>17</sup> performed subanalysis following propensity score matching, and the data were analyzed from the matched subgroup instead. The baseline characteristics, antiplatelet regimens and procedural details of the included studies are summarized in Tables 1–3. The qualities of included studies are described in Table 3.

### Major adverse cardiac events

As shown in Figure 2, the overall risk of MACE was not reduced significantly following TAPT (OR: 0.80; 95%



**Figure 1** Flow chart depicting the selection of the studies included in this meta-analysis.

**Table 1** Baseline characteristics of the included trials

| Study                               | Design | TAPT regimen  | DAPT regimen  |
|-------------------------------------|--------|---|---|
| DECLARE-LONG trial <sup>14</sup>    | RCT    | Loading: aspirin 200 mg, clopidogrel 300 mg, cilostazol 200 mg; maintenance: aspirin 200 mg/d, clopidogrel 75 mg/d, cilostazol 100 mg twice daily; >6 m                       | Loading: aspirin 200 mg, clopidogrel 300 mg; maintenance: aspirin 200 mg/d, clopidogrel 75 mg/d; >6 m               |
| DECLARE-LONG II trial <sup>16</sup> | RCT    | Loading: aspirin 200 mg, clopidogrel 300 mg, cilostazol 200 mg; maintenance: aspirin 200 mg/d, clopidogrel 75 mg/d, $\geq 12$ m; cilostazol 100 mg twice daily, for 8 m       | Loading: aspirin 200 mg, clopidogrel 300 mg; maintenance: aspirin 200 mg/d, clopidogrel 75 mg/d; $\geq 12$ m        |
| Lee et al <sup>9</sup>              | Obs    | DAPT + cilostazol, $\geq 3$ m   | Aspirin + clopidogrel or ticlopidine  |
| *COBIS II Registry <sup>17</sup>    | Obs    | Loading: aspirin 300 mg, clopidogrel 300–600 mg, cilostazol 200 mg; maintenance: aspirin indefinitely, clopidogrel 75 mg/d, $\geq 6$ m; + cilostazol                          | Loading: aspirin 300 mg, clopidogrel 300–600 mg; maintenance: aspirin indefinitely, clopidogrel 75 mg/d; $\geq 6$ m |
| Youn et al <sup>29</sup>            | RCT    | Loading: aspirin 300 mg, clopidogrel 300 mg, cilostazol 200 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, for 12 m; cilostazol 100 mg twice daily, for 3 m          | Loading: aspirin 300 mg, clopidogrel 300–600 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, for 12 m       |
| Kim et al <sup>25</sup>             | RCT    | Loading: aspirin 300 mg, clopidogrel 600 mg, cilostazol 400 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d; + cilostazol 200 mg, for 1 m                              | Loading: aspirin 300 mg, clopidogrel 600 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, for 1 m            |
| Chen et al <sup>10</sup>            | Obs    | Loading: aspirin 200 mg, clopidogrel 300–600 mg, cilostazol 200 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, $\geq 6$ m; cilostazol 100 mg twice daily, $\geq 1$ m | Loading: aspirin 200 mg, clopidogrel 300–600 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d; $\geq 6$ m     |
| Han et al <sup>27</sup>             | RCT    | Aspirin 300 mg/d for 1 m, followed by 100 mg/d indefinitely; clopidogrel 300–600 mg, followed by 75 mg/d, for 3–12 m; + cilostazol 100 mg twice daily, for 6 m                | Aspirin 300 mg/d for 1 m, followed by 100 mg/d indefinitely; clopidogrel 300–600 mg, followed by 75 mg/d, for 3–6 m |
| Ahn et al <sup>28</sup>             | RCT    | Loading: aspirin 200 mg, clopidogrel 300 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, for 24 m, cilostazol 100 mg twice daily                                      | Loading: aspirin 200 mg, clopidogrel 300 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, for 24 m           |
| Jeong et al <sup>26</sup>           | RCT    | Loading: aspirin 300 mg, clopidogrel 600 mg; maintenance: aspirin 200 mg/d, clopidogrel 75 mg/d, for 1 m; cilostazol 100 mg twice daily, for 1 m                              | Loading: aspirin 300 mg, clopidogrel 600 mg; maintenance: aspirin 200 mg/d, clopidogrel 75 mg/d, for 1 m            |
| Lee et al <sup>9</sup>              | Obs    | Loading: aspirin 300 mg, clopidogrel 450–600 mg, cilostazol 200 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, $\geq 6$ m; cilostazol 100 mg twice daily, $\geq 1$ m | Loading: aspirin 300 mg, clopidogrel 450–600 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, $\geq 6$ m     |

**Note:** \*Subgroup following propensity score matching.

**Abbreviations:** COBIS, COronary Bifurcation Stent; d, day; DAPT, dual antiplatelet therapy; DECLARE-LONG II, drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions; m, month; Obs, observational trials; RCT, randomized controlled trials; TAPT, triple antiplatelet therapy.

**Table 2** Characteristics of the patients' past medical histories among the included trials

| Study                               | TAPT/DAPT   |           |             |                 |             |                 |            | Follow-up |
|-------------------------------------|-------------|-----------|-------------|-----------------|-------------|-----------------|------------|-----------|
|                                     | Patients, n | Age, y    | Males, n    | Hypertension, n | Diabetes, n | Dyslipidemia, n | Smokers, n |           |
| DECLARE-LONG trial <sup>14</sup>    | 250/250     | 60.9/61.2 | 162/159     | 137/138         | 85/81       | 75/71           | 94/93      | 9 months  |
| DECLARE-LONG II trial <sup>16</sup> | 250/249     | 60.9/62.1 | 175/178     | 146/161         | 92/84       | 106/112         | 76/75      | 12 months |
| Lee et al <sup>9</sup>              | 124/121     | 63.8/64.9 | 90/70       | 75/71           | 44/31       | 88/84           | 32/25      | 12 months |
| *COBIS II Registry <sup>17</sup>    | 651/651     | 61.9/62.0 | 462/455     | 380/365         | 196/189     | NA              | 162/149    | 36 months |
| Youn et al <sup>29</sup>            | 308/307     | 65.0/64.2 | 194/197     | 210/202         | 100/95      | 152/146         | 149/135    | 12 months |
| Kim et al <sup>25</sup>             | 30/30       | 62.3/63.9 | 21/21       | 17/14           | 9/8         | 6/4             | 18/18      | 1 month   |
| Chen et al <sup>10</sup>            | 1,634/2,569 | 62.0/62.0 | 1,224/1,917 | 716/1,165       | 390/629     | 116/207         | 795/1,265  | 8 months  |
| Han et al <sup>27</sup>             | 604/608     | 59.6/60.2 | 446/443     | 350/341         | 141/122     | 275/276         | NA         | 12 months |
| Ahn et al <sup>28</sup>             | 64/66       | 62.1/65.2 | 39/42       | 28/24           | 14/15       | 16/13           | 28/30      | 24 months |
| Jeong et al <sup>26</sup>           | 30/30       | 61.3/64.0 | 21/22       | 17/11           | 9/4         | 9/13            | 16/21      | 1 month   |
| Lee et al <sup>9</sup>              | 195/532     | 69/72     | 125/317     | 100/263         | 48/149      | 15/39           | 94/241     | 12 months |

**Note:** \*Subgroup following propensity score matching.


**Abbreviations:** COBIS, COronary Bifurcation Stent; DAPT, dual antiplatelet therapy; DECLARE-LONG II, drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions; NA, not available; TAPT, triple antiplatelet therapy; y, years.

**Table 3** Angiographic and procedural characteristics

| Study                               | LM, n   | LAD, n    | LCX, n  | RCA, n  | Type of implanted stents | Stent length, mm | Stent number, n | Stent diameter, mm | Study quality  |
|-------------------------------------|---------|-----------|---------|---------|--------------------------|------------------|-----------------|--------------------|----------------|
| DECLARE-LONG trial <sup>14</sup>    | 0/0     | 155/152   | 23/29   | 72/69   | DES                      | 41.4/40.3        | 1.49/1.47       | NA                 | 2              |
| DECLARE-LONG II trial <sup>16</sup> | 0/0     | 149/155   | 40/29   | 61/65   | DES                      | 37.3/39.1        | 1.5/1.6         | NA                 | 5              |
| Lee et al <sup>9</sup>              | 124/121 | NA        | NA      | 50/51   | DES                      | 42.6/33.9        | 2.0/1.6         | 3.51/3.47          | 9 <sup>#</sup> |
| *COBIS II Registry <sup>17</sup>    | 212/267 | 300/287   | 55/76   | 24/21   | DES                      | NA               | 2.0/2.0         | NA                 | 8 <sup>#</sup> |
| Youn et al <sup>29</sup>            | NA      | NA        | NA      | 50/51   | DES                      | 51.1/49.7        | 2.3/2.2         | 3.08/3.05          | 3              |
| Kim et al <sup>25</sup>             | 0/0     | 12/16     | 3/6     | 15/8    | DES                      | NA               | NA              | NA                 | 2              |
| Chen et al <sup>10</sup>            | 23/21   | 866/1,387 | 169/242 | 576/919 | DES                      | 25.7/25.3        | 1.53/1.35       | 3.18/3.17          | 8 <sup>#</sup> |
| Han et al <sup>27</sup>             | 16/14   | 489/485   | 165/166 | 333/353 | DES/BMS                  | 37.9/38.8        | 1.58/1.56       | 3.12/3.16          | 3              |
| Ahn et al <sup>28</sup>             | 0/0     | 44/40     | 10/14   | 10/12   | DES                      | 24.5/25.0        | 2.38/2.36       | 2.9/2.8            | 2              |
| Jeong et al <sup>26</sup>           | 0/0     | 12/10     | 12/9    | 6/11    | DES                      | 33/31            | 1.4/1.3         | 3.2/3.0            | 3              |
| Lee et al <sup>9</sup>              | 2/14    | 100/248   | 26/77   | 66/188  | NA                       | 26.0/26.1        | 1.6/1.4         | 3.1/3.1            | 8 <sup>#</sup> |

**Notes:** <sup>#</sup>The qualities of observational trials were assessed by the Newcastle–Ottawa Scale, and the maximum score =9. The qualities of included randomized trials were assessed by the Jadad score. \*Subgroup following propensity score matching.

**Abbreviations:** BMS, bare metal stents; COBIS, COronary Bifurcation Stent; DECLARE-LONG II, drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions; DES, drug-eluting stent; LAD, left anterior descending artery; LCX, left circumflex artery; LM, left main coronary artery; RCA, right coronary artery; NA, not available.



**Figure 2** The ORs of MACE associated with TAPT compared with DAPT.

**Notes:** Forest plots of the efficacy and safety end points of the included trials. Weights are from random-effects analysis. \*Subgroup following propensity score matching.

**Abbreviations:** ACS, acute coronary syndrome; AMI, acute myocardial infarction; CI, confidence interval; COBIS, COronary Bifurcation Stent; DAPT, dual antiplatelet treatment; DECLARE-LONG II, drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions; MACE, major adverse cardiac events; OR, odds ratio; TAPT, triple antiplatelet treatment.

CI: 0.62–1.02,  $P=0.077$ ;  $I^2=58.9\%$ ,  $P=0.013$ ); a similar result was observed in the subgroup of complex lesions (OR: 0.89, 95% CI: 0.57–1.37,  $P=0.588$ ;  $I^2=64.3\%$ ,  $P=0.024$ ), while the contrary result was shown in the ACS subgroup (OR: 0.72, 95% CI: 0.61–0.85,  $P<0.001$ ;  $I^2=0\%$ ,  $P=0.407$ ). The results from the Egger’s test indicated no publication bias ( $P=0.918$ ), and the stability of results was proved by the sensitivity analysis.

### All-cause mortality

As depicted in Figure 3, lower overall risk of all-cause mortality was observed related to TAPT (OR: 0.75, 95% CI: 0.61–0.92,  $P=0.006$ ;  $I^2=38\%$ ,  $P=0.115$ ), which were mainly derived from the results of the ACS subgroup (OR: 0.62, 95% CI: 0.48–0.80,  $P<0.001$ ;  $I^2=0\%$ ,  $P=0.996$ ). No publication bias was found by the Egger’s test ( $P=0.250$ ).


The sensitivity analysis demonstrated these superior effects of TAPT.

### Myocardial infarction

There was no difference between the TAPT group and the DAPT group with respect to the incidence of MI (OR: 0.97, 95% CI: 0.63–1.51,  $P=0.901$ ;  $I^2=0\%$ ,  $P=0.989$ , Figure 4), as well as the ACS (OR: 0.87, 95% CI: 0.43–1.79,  $P=0.710$ ;  $I^2=0\%$ ,  $P=0.730$ ) and complex lesions subgroups (OR: 1.04, 95% CI: 0.60–1.81,  $P=0.894$ ;  $I^2=0\%$ ,  $P=1.000$ ). No publication bias was encountered via the Egger’s test ( $P=0.219$ ).

### Target vessel revascularization


The incidence of TVR did not differ significantly between the two groups (OR: 0.90, 95% CI: 0.65–1.23,  $P=0.491$ ;  $I^2=51.9\%$ ,  $P=0.034$ , Figure 5), and similar results could also



**Figure 3** The ORs of all-cause mortality associated with TAPT compared with DAPT.

**Notes:** Forest plots of the efficacy and safety end points of the included trials. \*Subgroup following propensity score matching.

**Abbreviations:** ACS, acute coronary syndrome; AMI, acute myocardial infarction; CI, confidence interval; COBIS, COronary Bifurcation Stent; DAPT, dual antiplatelet treatment; DECLARE-LONG II, drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions; OR, odds ratio; TAPT, triple antiplatelet treatment.



**Figure 4** The ORs of myocardial infarction associated with TAPT compared with DAPT.

**Notes:** Forest plots of the efficacy and safety end points of the included trials. \*Subgroup following propensity score matching.

**Abbreviations:** ACS, acute coronary syndrome; AMI, acute myocardial infarction; CI, confidence interval; COBIS, COronary Bifurcation Stent; DAPT, dual antiplatelet treatment; DECLARE-LONG II, drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions; OR, odds ratio; TAPT, triple antiplatelet treatment.

be obtained in both subgroups (complex lesions: OR: 0.81, 95% CI: 0.46–1.41,  $P=0.450$ ;  $I^2=66.6\%$ ,  $P=0.017$ ; ACS: OR: 0.95, 95% CI: 0.65–1.40,  $P=0.802$ ;  $I^2=33.2\%$ ,  $P=0.213$ ). Egger's test indicated that there was no publication bias ( $P=0.348$ ).

## Stroke

TAPT was not associated with lower risk of stroke compared to DAPT (OR: 0.63, 95% CI: 0.32–1.21,  $P=0.163$ ;  $I^2=0\%$ ,  $P=0.790$ , Figure 6). In the ACS or the complex lesions subgroup, the incidence of stroke did not differ significantly between the triple treatment and the dual treatment groups (complex lesions: OR: 0.89, 95% CI: 0.36–2.21,  $P=0.807$ ;  $I^2=0\%$ ,  $P=0.681$ ; ACS: OR: 0.43, 95% CI: 0.16–1.16,  $P=0.094$ ;  $I^2=0\%$ ,  $P=0.798$ ). The results from the Egger's test suggested no publication bias regarding the incidence of stroke ( $P=0.762$ ).


## Safety end points

### Definite/probable ST

The comparison between TAPT and DAPT showed no significant difference with respect to the risk of definite/probable ST (OR: 1.70, 95% CI: 0.85–3.38,  $P=0.133$ ;  $I^2=0\%$ ,  $P=0.843$ , Figure 7), while similar results were observed in the ACS subgroup (OR: 0.67, 95% CI: 0.11–4.02,  $P=0.661$ ) and complex lesions subgroup (OR: 2.00, 95% CI: 0.94–4.30,  $P=0.074$ ;  $I^2=0\%$ ,  $P=0.926$ ). No publication bias was observed based on the results of the Egger's test ( $P=0.792$ ).

### Bleeding

The incidence of major or minor bleeding was not increased with TAPT compared with DAPT (major bleeding: OR: 1.07, 95% CI: 0.60–1.90,  $P=0.809$ ;  $I^2=0\%$ ,  $P=0.637$ , Figure 8; minor bleeding: OR: 1.12, 95% CI: 0.68–1.86,



**Figure 5** The ORs of TVR associated with TAPT compared with DAPT.

**Notes:** Forest plots of the efficacy and safety end points of the included trials. Weights are from random-effects analysis. \*Subgroup following propensity score matching.  
**Abbreviations:** ACS, acute coronary syndrome; AMI, acute myocardial infarction; CI, confidence interval; COBIS, COronary Bifurcation Stent; DAPT, dual antiplatelet treatment; DECLARE-LONG II, drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions; OR, odds ratio; TAPT, triple antiplatelet treatment; TVR, target vessel revascularization.


$P=0.649$ ;  $I^2=0%$ ,  $P=0.929$ , Figure 9). No publication bias was observed ( $P=0.675$  and  $P=0.727$  for major and minor bleeding, respectively).

## Discussion

In this meta-analysis, the major finding was that TAPT after stent implantation seemed to be associated with lower incidence of MACE, compared to DAPT, among ACS patients, which was thought mainly to result from the significant reduction in risk of all-cause mortality in this specific subset. The risk of bleeding, including major and minor bleeding, was not increased after TAPT, and the triple regimen did not reduce the incidence of MI, TVR, ST, and stroke.

The optimal antiplatelet regimen after intracoronary intervention among patients suffering from CAD has remained controversial. The routine dual regimen is used widely for these patients, particularly for patients with conditions

complicated with diabetes mellitus (DM), complex coronary artery lesions, and ACS, in whom high risk of developing thrombotic events after stent implantation has been found. After treatment with the conventional dual antiplatelet regimen after stenting procedure, ~10% of patients still developed thrombotic events and subsequently faced higher incidence of adverse events.<sup>4,5</sup> Instead, a triple regimen adding cilostazol to the routine DAPT for these patients was considered to obtain better outcomes. Recently, two large RCTs published by Lee et al<sup>16</sup> and Han et al<sup>27</sup> indicated ideal results of the triple regimen. In the Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions (DECLARE-LONG II) trial,<sup>16</sup> 499 patients undergoing long stent implantation (stent length:  $\geq 30$  mm) were enrolled, and decreased extent of late luminal loss, resulting in reduced risk of 12-month TLR, was observed. Moreover, Han et al<sup>27</sup> demonstrated that TAPT



**Figure 6** The ORs of stroke associated with TAPT compared with DAPT.


**Notes:** Forest plots of the efficacy and safety end points of the included trials. \*Subgroup following propensity score matching.

**Abbreviations:** ACS, acute coronary syndrome; AMI, acute myocardial infarction; CI, confidence interval; COBIS, COronary Bifurcation Stent; DAPT, dual antiplatelet treatment; DECLARE-LONG II, drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions; OR, odds ratio; TAPT, triple antiplatelet treatment.

reduced long-term cardiac and cerebral events after PCI in patients suffering from ACS (TAPT vs DAPT: 10.3% vs 15.1%,  $P=0.011$ ) by analyzing the data of 1,212 patients. Bundhun et al<sup>13</sup> recently performed a meta-analysis involving patients with complications of CAD and DM undergoing stent implantation; significant reduced risk of MACE was found in the triple group without any increase in risk of bleeding, the results being in line with the mentioned RCTs. However, several other clinical trials showed contrary results. The COBIS II Registry<sup>17</sup> performed a subgroup analysis after propensity score matching, in which 1,302 patients with bifurcation lesions were divided into two groups at a 1:1 ratio and repeatedly analyzed. The final results showed that TAPT had no beneficial effect in terms of improving long-term clinical outcomes, similar to the results from another clinical trial.<sup>18</sup> In the retrospective cohort, a total of 245 patients (124 for TAPT, 121 for DAPT) presenting with

unprotected LM disease were enrolled, and only limited or even no benefits of triple regimen were shown in terms of reducing risk of MACE, including death, MI, TVR, or stroke. The conflicting data from these clinical trials indicated that the superiority of TAPT compared to DAPT post-PCI still remains controversial and that there are only specific patient populations that might truly benefit from the regimen.

In this meta-analysis, lower incidence of MACE was observed in the subset of ACS, which might mainly be due to the significant reduced risk of all-cause mortality in this subgroup. To our knowledge, the acute phase of ACS was commonly complicated by the prothrombotic and inflammatory environment, which might aggravate myocardial injury and delay myocardial recovery, leading to worse clinical outcomes although early revascularization had been performed. Furthermore, these negative reactions might also be enhanced by the primary PCI if the procedure lasted a



**Figure 7** The ORs of stent thrombosis associated with TAPT compared with DAPT.

**Notes:** Forest plots of the efficacy and safety end points of the included trials. \*Subgroup following propensity score matching.

**Abbreviations:** ACS, acute coronary syndrome; AMI, acute myocardial infarction; CI, confidence interval; COBIS, COronary Bifurcation Stent; DAPT, dual antiplatelet treatment; DECLARE-LONG II, drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions; OR, odds ratio; TAPT, triple antiplatelet treatment.

very long time or if multiple stents were implanted during the primary procedure. It should be noted that the routine dual regimen (aspirin plus a P2Y12 receptor antagonist) post-PCI could only have limited effects in terms of preventing these negative reactions if the patients had HTPR.<sup>6</sup> The new triple regimen of adding cilostazol to aspirin plus clopidogrel for antiplatelet therapy is considered to be helpful. Cilostazol is a selective inhibitor of phosphodiesterase III, which is known to hydrolyze cyclic adenosine monophosphate (cAMP), resulting in the accumulation of cAMP in vascular smooth muscle cells (VSMCs), which can suppress platelet aggregation, thus differing from aspirin or clopidogrel in the antiplatelet mechanism.<sup>30</sup> It might be more helpful in diminishing the prothrombotic and inflammatory response because cilostazol has additional effects in terms of suppressing platelet aggregation. The combination of the three agents might decrease HTPR and lead to intensified antiplatelet effect, which could reduce subsequent damage to

myocardial cells and improve myocardial recovery, leading to better clinical outcomes.

Additionally, results from this meta-analysis showed that TAPT had no positive effects in terms of reducing the incidence of TVR, which are contrary to the results obtained by several other meta-analyses.<sup>11,12,31</sup> Lee et al<sup>16</sup> had reported that TAPT played a positive role in reducing the risk of TLR among 499 patients undergoing long stent implantation. In their opinion, the possible reasons might be that cilostazol-induced cAMP accumulation inhibits the activation of mitogen-activated protein kinase while upregulating the antioncogenes p53 and p21, leading to induced apoptosis in VSMCs and resulting in the antiproliferative effects on VSMCs.<sup>32,33</sup> On the other hand, P-selectin-mediated platelet activation and subsequent Mac-1-mediated leukocyte activation are considered to be related with late lumen loss after coronary stenting, while cilostazol plays an important role in inhibiting their expression.<sup>34</sup> However, several other





mortality among patients suffering from ACS, without any increased risk of bleeding. However, more powerful randomized clinical trials comparing TAPT to DAPT after PCI procedure in such patients with more precise subgroups are still warranted to guide clinical application of this triple antiplatelet regimen.

## Acknowledgment

The study was supported by the Jiangsu Provincial Special Program of Medical Science (BL2013001).

## Author contributions

FZG and DGB were involved in the design, literature search, assessment of study quality and drafting of the manuscript. Disagreements were resolved by LXB. FZG and DGB performed statistical analysis and critically revised the manuscript. GXF and GYL constructed the maps. TNL critically revised the original study design and the manuscript. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

## Disclosure

The authors report no conflicts of interest in this work.

## References

- O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;127(4):e362–e425.
- Grove EL, Wurtz M, Thomas MR, Kristensen SD. Antiplatelet therapy in acute coronary syndromes. *Expert Opin Pharmacother*. 2015;16(14):2133–2147.
- Cowley MJ, Kuritzky L. Developments in antiplatelet therapy for acute coronary syndromes and considerations for long-term management. *Curr Med Res Opin*. 2009;25(6):1477–1490.
- Iakovou I, Schmidt T, Bonizzi E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. *JAMA*. 2005;293(17):2126–2130.
- Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. *Lancet*. 2007;369(9562):667–678.
- Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. *JAMA*. 2011;306(11):1215–1223.
- Cone J, Wang S, Tandon N, et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. *J Cardiovasc Pharmacol*. 1999;34(4):497–504.
- Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. *Atheroscler Suppl*. 2005;6(4):3–11.
- Lee KH, Ahn Y, Kim SS, et al; KAMIR (Korea Acute Myocardial Infarction Registry) Investigators. Comparison of triple anti-platelet therapy and dual anti-platelet therapy in patients with acute myocardial infarction who had no-reflow phenomenon during percutaneous coronary intervention. *Circ J*. 2013;77(12):2973–2981.
- Chen KY, Rha SW, Li YJ, et al; Korea Acute Myocardial Infarction Registry Investigators. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Circulation*. 2009;119(25):3207–3214.
- Chen Y, Zhang Y, Tang Y, Huang X, Xie Y. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. *Curr Med Res Opin*. 2014;30(1):37–49.
- Sakurai R, Koo BK, Kaneda H, Bonneau HN, Nagai R. Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. *Int J Cardiol*. 2013;167(5):2250–2258.
- Bundhun PK, Qin T, Chen MH. Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. *BMC Cardiovasc Disord*. 2015;15:118.
- Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). *J Am Coll Cardiol*. 2008;51(12):1181–1187.
- Ha SJ, Kim SJ, Hwang SJ, et al. Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention. *Coron Artery Dis*. 2013;24(8):690–697.
- Lee SW, Park SW, Kim YH, et al; DECLARE-LONG II Study Investigators. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions) trial. *J Am Coll Cardiol*. 2011;57(11):1264–1270.
- Song PS, Song YB, Yang JH, et al. Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary Bifurcation Stent) II Registry. *Heart Vessels*. 2015;30(4):458–468.
- Lee HJ, Yu CW, Hwang HK, et al. Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease. *Coron Artery Dis*. 2013;24(7):542–548.
- Biondi-Zoccai GG, Abbate A, Agostoni P, et al. Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: a meta-regression. *Am Heart J*. 2005;149(3):504–511.
- Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials*. 1996;17(1):1–12.
- Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7–8, 2006. *Circulation*. 2007;115(17):2352–2357.
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009;339:b2700.
- Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629–634.
- Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). *Am J Cardiol*. 2007;100(7):1103–1108.
- Kim JY, Lee K, Shin M, et al. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. *Circ J*. 2007;71(12):1867–1872.

26. Jeong YH, Hwang JY, Kim IS, et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. *Circ Cardiovasc Interv.* 2010; 3(1):17–26.
27. Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. *Am Heart J.* 2009;157(4):733–739.
28. Ahn CM, Hong SJ, Park JH, Kim JS, Lim DS. Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. *Heart Vessels.* 2011;26(5):502–510.
29. Youn YJ, Lee JW, Ahn SG, et al. Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease. *Am Heart J.* 2014;167(2):241.e1–248.e1.
30. Savi P, Zacharyus JL, Delesque-Touchard N, et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. *Proc Natl Acad Sci U S A.* 2006;103(29): 11069–11074.
31. Chen J, Meng H, Xu L, et al. Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. *J Thromb Thrombolysis.* 2015; 39(1):23–34.
32. Ito C, Kusano E, Furukawa Y, et al. Modulation of the erythropoietin-induced proliferative pathway by cAMP in vascular smooth muscle cells. *Am J Physiol Cell Physiol.* 2002;283(6):C1715–C1721.
33. Hayashi S, Morishita R, Matsushita H, et al. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. *Hypertension.* 2000;35(1 pt 2):237–243.
34. Inoue T, Uchida T, Sakuma M, et al. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. *J Am Coll Cardiol.* 2004;44(7):1408–1414.

## Drug Design, Development and Therapy

### Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are the features of the journal, which

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>

Dovepress

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.